the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient

NCT01766375 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Cyclosporin A,mycophenolate mofetil,Methotrexate

Sponsor

Guangxi Medical University